A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Azilsartan medoxomil and chlorthalidone in Essential Hypertension, sponsored by Takeda. Completed at 94 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-07.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 10 in phase 3, and was the 9th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2010.
This study's enrollment of 1,071 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 837 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Essential Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 12 in phase 3, and was the 9th registered.
Takeda’s Essential Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 15 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.
According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully.
Treatment algorithms for essential hypertension commonly include thiazides or thiazide-like diuretics, either alone or as part of combination treatment. Chlorthalidone is a commercially available, orally administered thiazide-type diuretic agent.
TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker developed by Takeda to treat participants with essential hypertension.
This study will compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone (TAK-491CLD) fixed-dose combination to olmesartan medoxomil plus hydrochlorothiazide fixed-dose combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Olmesartan medoxomil and hydrochlorothiazide
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Also known as: azilsartan medoxomil plus chlorthalidone, TAK-491CLD
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Also known as: azilsartan medoxomil plus chlorthalidone, TAK-491CLD
Drug pages: Olmesartan Medoxomil · Hydrochlorothiazide
Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks.
Also known as: Benicar HCT®
Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 12.
Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
The change in sitting trough clinic systolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline, Week 4 and Week 8.
Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.
The change in sitting trough clinic diastolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average (arithmetic mean) of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline, Week 4, Week 8 and Week 12.
Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
The change in trough systolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 12.
Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
The change in trough diastolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 12.
Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
The change in 24-hour mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 12.
Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
The change in 24-hour mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 12.
Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive).
Time frame: Baseline and Week 12.
Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive).
Time frame: Baseline and Week 12.
Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
The change in the mean nighttime (12am to 6am) systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive).
Time frame: Baseline and Week 12.
Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
The change in the mean nighttime (12am to 6am) diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive).
Time frame: Baseline and Week 12.
Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
The change in the mean 12 hour systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements.
Time frame: Baseline and Week 12.
Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
The change in the mean 12 hour diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements.
Time frame: Baseline and Week 12.
Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour.
Time frame: Baseline and Week 12.
Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour.
Time frame: Baseline and Week 12.
Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.
Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the non-missing values of the 3serial trough sitting systolic blood pressure measurements.
Time frame: Baseline, Week 4, Week 8 and Week 12.
Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.
Time frame: Baseline, Week 4, Week 8 and Week 12.
Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the non-missing values of the 3 serial trough sitting blood pressure measurements.
Time frame: Baseline, Week 4, Week 8 and Week 12.
Participants enrolled at 130 investigative sites in Canada and the United States from 08 December 2009 to 04 November 2010.
| Milestone | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Started | 355 | 352 | 364 |
| Completed | 300 | 275 | 317 |
| Not completed | 55 | 77 | 47 |
| Withdrew: Adverse event | 28 | 51 | 26 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 4 | 5 | 5 |
| Withdrew: Withdrawal by subject | 17 | 14 | 11 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 |
| Withdrew: Other | 6 | 4 | 3 |
The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure. | -42.5 ± 0.81 | -44.0 ± 0.83 | -37.1 ± 0.80 |
The change in sitting trough clinic systolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | -34.7 ± 0.77 | -36.7 ± 0.79 | -29.7 ± 0.76 |
| Week 8 (n=344; n=330; n=353) | -39.1 ± 0.78 | -39.4 ± 0.80 | -33.5 ± 0.77 |
The change in sitting trough clinic diastolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average (arithmetic mean) of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | -14.9 ± 0.46 | -15.8 ± 0.47 | -11.7 ± 0.45 |
| Week 8 (n=344; n=330; n=353) | -17.0 ± 0.48 | -17.7 ± 0.49 | -13.9 ± 0.48 |
| Week 12 (n=344; n=330; n=354) | -18.8 ± 0.47 | -20.5 ± 0.48 | -16.4 ± 0.46 |
The change in trough systolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring. | -32.9 ± 0.86 | -34.9 ± 0.90 | -25.9 ± 0.85 |
The change in trough diastolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring. | -19.8 ± 0.55 | -20.2 ± 0.57 | -16.0 ± 0.54 |
The change in 24-hour mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring. | -33.9 ± 0.76 | -36.3 ± 0.79 | -27.5 ± 0.75 |
The change in 24-hour mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring. | -19.4 ± 0.45 | -20.7 ± 0.46 | -16.2 ± 0.44 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive).
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring. | -35.3 ± 0.80 | -37.9 ± 0.84 | -28.8 ± 0.79 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive).
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring. | -20.1 ± 0.48 | -21.8 ± 0.50 | -17.0 ± 0.47 |
The change in the mean nighttime (12am to 6am) systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive).
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring. | -29.6 ± 0.78 | -31.8 ± 0.81 | -23.9 ± 0.77 |
The change in the mean nighttime (12am to 6am) diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive).
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring. | -17.5 ± 0.48 | -18.0 ± 0.50 | -14.0 ± 0.48 |
The change in the mean 12 hour systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring. | -36.2 ± 0.86 | -38.8 ± 0.89 | -29.7 ± 0.85 |
The change in the mean 12 hour diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring. | -20.4 ± 0.51 | -22.2 ± 0.53 | -17.5 ± 0.50 |
The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| 0 to 1 Hour (n=232; n=212; n=237) | -33.6 ± 0.96 | -36.2 ± 1.00 | -26.8 ± 0.95 |
| 1 to 2 Hour (n=232; n=214; n=238) | -33.4 ± 0.98 | -36.4 ± 1.02 | -27.5 ± 0.97 |
| 2 to 3 Hour (n=232; n=214; n=238) | -36.7 ± 1.02 | -39.3 ± 1.06 | -30.0 ± 1.00 |
| 3 to 4 Hour (n=232; n=214; n=238) | -36.6 ± 1.07 | -40.3 ± 1.12 | -29.6 ± 1.06 |
| 4 to 5 Hour (n=232; n=214; n=238) | -36.8 ± 1.07 | -40.8 ± 1.11 | -30.1 ± 1.06 |
| 5 to 6 Hour (n=232; n=214; n=238) | -37.2 ± 1.02 | -41.2 ± 1.06 | -31.5 ± 1.00 |
| 6 to 7 Hour (n=232; n=214; n=238) | -36.3 ± 1.04 | -38.6 ± 1.08 | -29.8 ± 1.02 |
| 7 to 8 Hour (n=232; n=214; n=238) | -37.2 ± 1.02 | -38.5 ± 1.06 | -29.7 ± 1.00 |
| 8 to 9 Hour (n=232; n=214; n=238) | -37.3 ± 1.02 | -38.1 ± 1.06 | -30.5 ± 1.01 |
| 9 to 10 Hour (n=232; n=214; n=238) | -36.9 ± 0.99 | -38.0 ± 1.04 | -30.8 ± 0.98 |
| 10 to 11 Hour (n=232; n=214; n=238) | -36.1 ± 1.02 | -37.6 ± 1.06 | -29.4 ± 1.01 |
| 11 to 12 Hour (n=232; n=214; n=238) | -35.2 ± 1.01 | -38.2 ± 1.05 | -29.3 ± 1.00 |
| 12 to 13 Hour (n=232; n=214; n=238) | -34.8 ± 1.05 | -36.2 ± 1.09 | -27.7 ± 1.04 |
| 13 to 14 Hour (n=232; n=214; n=238) | -34.1 ± 1.06 | -35.3 ± 1.11 | -26.4 ± 1.05 |
| 14 to 15 Hour (n=232; n=214; n=238) | -33.4 ± 1.06 | -35.0 ± 1.10 | -26.2 ± 1.04 |
| 15 to 16 Hour (n=232; n=214; n=238) | -30.9 ± 0.99 | -32.9 ± 1.03 | -25.3 ± 0.97 |
| 16 to 17 Hour (n=232; n=214; n=238) | -29.6 ± 0.94 | -31.1 ± 0.98 | -24.5 ± 0.93 |
| 17 to 18 Hour (n=231; n=214; n=238) | -28.5 ± 0.93 | -30.8 ± 0.97 | -23.1 ± 0.92 |
| 18 to 19 Hour (n=232; n=214; n=238) | -29.5 ± 0.90 | -31.9 ± 0.94 | -24.3 ± 0.89 |
| 19 to 20 Hour (n=232; n=214; n=238) | -29.7 ± 0.89 | -32.5 ± 0.93 | -23.5 ± 0.88 |
| 20 to 21 Hour (n=232; n=214; n=238) | -28.2 ± 0.94 | -31.2 ± 0.98 | -23.0 ± 0.92 |
| 21 to 22 Hour (n=232; n=214; n=238) | -30.6 ± 0.95 | -32.8 ± 0.99 | -24.6 ± 0.93 |
| 22 to 23 Hour (n=232; n=214; n=238) | -32.9 ± 0.94 | -34.0 ± 0.98 | -25.9 ± 0.92 |
| 23 to 24 Hour (n=232; n=214; n=238) | -33.1 ± 0.92 | -35.8 ± 0.96 | -26.1 ± 0.91 |
The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour.
| mmHg | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| 0 to 1 Hour (n=232; n=212; n=237) | -18.2 ± 0.59 | -20.4 ± 0.62 | -15.2 ± 0.59 |
| 1 to 2 Hour (n=232; n=214; n=238) | -18.8 ± 0.65 | -20.9 ± 0.67 | -15.9 ± 0.64 |
| 2 to 3 Hour (n=232; n=214; n=238) | -21.2 ± 0.66 | -23.4 ± 0.69 | -17.7 ± 0.65 |
| 3 to 4 Hour (n=232; n=214; n=238) | -20.8 ± 0.69 | -23.7 ± 0.72 | -18.2 ± 0.68 |
| 4 to 5 Hour (n=232; n=214; n=238) | -21.7 ± 0.67 | -23.7 ± 0.70 | -17.9 ± 0.66 |
| 5 to 6 Hour (n=232; n=214; n=238) | -20.9 ± 0.67 | -23.6 ± 0.70 | -19.0 ± 0.66 |
| 6 to 7 Hour (n=232; n=214; n=238) | -20.8 ± 0.65 | -22.0 ± 0.67 | -18.0 ± 0.64 |
| 7 to 8 Hour (n=232; n=214; n=238) | -20.5 ± 0.66 | -21.9 ± 0.69 | -17.7 ± 0.65 |
| 8 to 9 Hour (n=232; n=214; n=238) | -20.7 ± 0.67 | -21.5 ± 0.69 | -17.9 ± 0.66 |
| 9 to 10 Hour (n=232; n=214; n=238) | -21.0 ± 0.66 | -21.9 ± 0.68 | -18.3 ± 0.65 |
| 10 to 11 Hour (n=232; n=214; n=238) | -19.7 ± 0.67 | -20.7 ± 0.70 | -16.7 ± 0.66 |
| 11 to 12 Hour (n=232; n=214; n=238) | -19.3 ± 0.69 | -21.2 ± 0.72 | -17.0 ± 0.68 |
| 12 to 13 Hour (n=232; n=214; n=238) | -19.2 ± 0.73 | -20.3 ± 0.76 | -16.0 ± 0.72 |
| 13 to 14 Hour (n=232; n=214; n=238) | -19.6 ± 0.72 | -19.5 ± 0.75 | -15.3 ± 0.71 |
| 14 to 15 Hour (n=232; n=214; n=238) | -18.9 ± 0.72 | -19.7 ± 0.75 | -15.4 ± 0.71 |
| 15 to 16 Hour (n=232; n=214; n=238) | -17.8 ± 0.65 | -18.6 ± 0.68 | -14.5 ± 0.65 |
| 16 to 17 Hour (n=232; n=214; n=238) | -17.2 ± 0.65 | -16.9 ± 0.68 | -13.9 ± 0.64 |
| 17 to 18 Hour (n=231; n=214; n=238) | -16.6 ± 0.64 | -17.1 ± 0.66 | -13.2 ± 0.63 |
| 18 to 19 Hour (n=232; n=214; n=238) | -17.4 ± 0.65 | -18.1 ± 0.67 | -14.3 ± 0.64 |
| 19 to 20 Hour (n=232; n=214; n=238) | -17.8 ± 0.60 | -18.5 ± 0.63 | -13.8 ± 0.60 |
| 20 to 21 Hour (n=232; n=214; n=238) | -16.7 ± 0.64 | -18.4 ± 0.67 | -13.9 ± 0.63 |
| 21 to 22 Hour (n=232; n=214; n=238) | -17.8 ± 0.66 | -18.5 ± 0.69 | -14.7 ± 0.65 |
| 22 to 23 Hour (n=232; n=214; n=238) | -19.5 ± 0.62 | -19.6 ± 0.65 | -15.6 ± 0.62 |
| 23 to 24 Hour (n=232; n=214; n=238) | -20.2 ± 0.60 | -21.0 ± 0.62 | -16.4 ± 0.59 |
Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the non-missing values of the 3serial trough sitting systolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | 87.8 | 90.0 | 79.8 |
| Week 8 (n=344; n=330; n=353) | 93.3 | 92.4 | 85.6 |
| Week 12 (n=344; n=330; n=354) | 93.0 | 94.2 | 89.3 |
Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | 89.2 | 89.7 | 85.2 |
| Week 8 (n=344; n=330; n=353) | 90.7 | 90.9 | 87.8 |
| Week 12 (n=344; n=330; n=354) | 94.5 | 95.8 | 91.5 |
Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the non-missing values of the 3 serial trough sitting blood pressure measurements.
| percent of participants | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | 81.3 | 84.8 | 74.4 |
| Week 8 (n=344; n=330; n=353) | 88.1 | 87.3 | 81.0 |
| Week 12 (n=344; n=330; n=354) | 91.3 | 92.4 | 84.7 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | — | 1/355 (0.3%) | 141/355 (39.7%) |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | — | 10/352 (2.8%) | 144/352 (40.9%) |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | — | 8/364 (2.2%) | 94/364 (25.8%) |
| Event | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| HypotensionVascular disorders | 0/355 | 3/352 | 0/364 |
| DehydrationMetabolism and nutrition disorders | 0/355 | 2/352 | 0/364 |
| SyncopeNervous system disorders | 0/355 | 2/352 | 0/364 |
| AnaemiaBlood and lymphatic system disorders | 0/355 | 1/352 | 0/364 |
| ArrhythmiaCardiac disorders | 0/355 | 1/352 | 0/364 |
| Cardiac failure congestiveCardiac disorders | 0/355 | 1/352 | 0/364 |
| VertigoEar and labyrinth disorders | 0/355 | 1/352 | 0/364 |
| VomitingGastrointestinal disorders | 0/355 | 1/352 | 0/364 |
| Non-cardiac chest painGeneral disorders | 1/355 | 1/352 | 0/364 |
| Lobar pneumoniaInfections and infestations | 0/355 | 1/352 | 0/364 |
| Event | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD |
|---|---|---|---|
| Blood creatinine increasedInvestigations | 66/355 | 78/352 | 34/364 |
| DizzinessNervous system disorders | 41/355 | 58/352 | 29/364 |
| FatigueGeneral disorders | 33/355 | 14/352 | 16/364 |
| HeadacheNervous system disorders | 19/355 | 13/352 | 26/364 |
| Blood uric acid increasedInvestigations | 19/355 | 17/352 | 12/364 |
| Age Continuous(years) | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Mean | 56.4 ± 10.49 | 56.7 ± 10.07 | 56.7 ± 10.86 | 56.6 ± 10.47 |
| Age, Customized(participants) | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| <45 years | 46 | 33 | 46 | 125 |
| Between 45 to 64 years | 235 | 241 | 234 | 710 |
| ≥65 years | 74 | 78 | 84 | 236 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Female | 132 | 151 | 159 | 442 |
| Male | 223 | 201 | 205 | 629 |
| Ethnicity (NIH/OMB)(Participants) | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 28 | 36 | 34 | 98 |
| Not Hispanic or Latino | 248 | 241 | 251 | 740 |
| Unknown or Not Reported | 79 | 75 | 79 | 233 |
| Race (NIH/OMB)(participants) | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 5 | 5 | 12 |
| Asian | 13 | 11 | 11 | 35 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 2 | 3 |
| Black or African American | 80 | 80 | 80 | 240 |
| White | 261 | 258 | 267 | 786 |
| More than one race | 1 | 2 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| United States | 276 | 277 | 285 | 838 |
| Canada | 79 | 75 | 79 | 233 |
| Weight(kg) | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Mean | 92.34 ± 20.296 | 91.47 ± 20.987 | 90.83 ± 18.590 | 91.54 ± 19.960 |
| Height(cm) | Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | Total |
|---|---|---|---|---|
| Mean | 171.2 ± 10.15 | 169.3 ± 10.88 | 169.4 ± 10.15 | 170.0 ± 10.42 |
2 further baseline measures are reported on the registry.
The record gives a start of Jan 2010, a primary completion of Oct 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone